• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Dips Over 300 Points; Crude Oil Rises Sharply

    10/7/22 12:11:26 PM ET
    $AEHR
    $ATXI
    $BBLG
    $NINE
    Electrical Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEHR alert in real time by email

    U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 300 points on Friday.

    The Dow traded down 1.64% to 29,435.14 while the NASDAQ fell 3% to 10,741.38. The S&P 500 also fell, dropping, 2.17% to 3,663.23.

    Also check this: Dow Dips Over 300 Points, Volatility In Markets Increases


    Leading and Lagging Sectors


    Energy shares jumped by 0.8% on Friday. Leading the sector was strength from TransGlobe Energy Corporation (NYSE:TGA) and Nine Energy Service, Inc. (NYSE:NINE).


    In trading on Friday, information technology shares fell by 3.4%.


    Top Headline

     

    The US economy added 263,000 jobs in September, the least since April 2021, but still above analysts’ estimates of 250,000. The US unemployment rate declined to 3.5% in September, while average hourly earnings rose 0.3% to $32.46 in September.


    Equities Trading UP

     

    • Innovative Eyewear, Inc. (NASDAQ:LUCY) shares shot up 93% to $3.15 on abnormally-high volume. The company released its October investor presentation yesterday.
    • Shares of Aehr Test Systems (NASDAQ:AEHR) got a boost, shooting 19% to $16.50 after the company announced better-than-expected Q1 EPS and sales results and issued guidance.
    • Plus Therapeutics, Inc. (NASDAQ:PSTV) shares were also up, gaining 17% to $0.6370 after JonesTrading initiated coverage on the stock with a Buy rating and $5 price target.


    Equities Trading DOWN

    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) shares tumbled 57% to $2.68 after the company priced a roughly 3.6 million unit offering at $3.30 per unit.
    • Shares of InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) were down 39% to $4.88 after the company announced $9 million registered direct and private placement offerings priced at-the-market under Nasdaq rules.
    • Bone Biologics Corporation (NASDAQ:BBLG) was down, falling 34% to $0.59 after the company priced a 3,777,778 unit offering at $1.35 per unit.


    Also check out: Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday


    Commodities

    In commodity news, oil traded up 3.2% to $91.32, while gold traded down 0.6% at $1,711.10.


    Silver traded down 1.4% to $20.365 on Friday while copper fell 1.5% to $3.3945.


    Euro zone


    European shares were mostly lower today. The eurozone’s STOXX 600 fell 1%, London’s FTSE 100 rose 0.01% while Spain’s IBEX 35 Index fell 0.83%. The German DAX dropped 1.25%, French CAC 40 fell 1.01% and Italy’s FTSE MIB Index fell 0.88%.

    France recorded a current account deficit of EUR 5.1 billion in August versus a EUR 5.3 billion gap in the prior month, while trade deficit increased to EUR 15.3 billion in August from revised EUR 14.8 billion in July.

    Labor productivity in the UK rose by 0.3% on quarter during the three months to June, while Halifax house price index rose 9.9% year-over-year in September. Industrial production in Germany declined 0.8% month-over-month in August, while retail sales fell 1.3% month-over-month in August. Import prices in Germany climbed by 32.7% year-over-year in August.

     

    Economics

     

    • The US economy added 263,000 jobs in September, the least since April 2021, but still above analysts’ estimates of 250,000. The US unemployment rate declined to 3.5% in September, while average hourly earnings rose 0.3% to $32.46 in September.
    • Wholesale inventories rose by 1.3% from a month ago to $912.6 billion in August following a 0.6% increase in the prior month.
    • The Baker Hughes North American rig count report for the latest week is scheduled for release at 1:00 p.m. ET.
    • Data on consumer credit for August will be released at 3:00 p.m. ET. Consumer credit is projected to rise $25.0 billion in August following a $23.8 billion increase in the previous month.


    Check out this: Investor Fear Increases Ahead Of US Jobs Data


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 98,474,750 cases with around 1,087,350 deaths. India confirmed a total of at least 44,606,460 cases and 528,750 deaths, while France reported over 35,705,230 COVID-19 cases with 155,360 deaths. In total, there were at least 625,747,770 cases of COVID-19 worldwide with more than 6,558,400 deaths.

    Get the next $AEHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEHR
    $ATXI
    $BBLG
    $NINE

    CompanyDatePrice TargetRatingAnalyst
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    Aehr Test Systems
    $AEHR
    12/17/2025$29.00Buy
    Lake Street
    PLUS THERAPEUTICS Inc.
    $PSTV
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    PLUS THERAPEUTICS Inc.
    $PSTV
    3/17/2025$9.00Buy
    D. Boral Capital
    Aehr Test Systems
    $AEHR
    7/17/2024$12.00 → $25.00Hold → Buy
    Craig Hallum
    Aehr Test Systems
    $AEHR
    3/26/2024$12.00Buy → Hold
    Craig Hallum
    Aehr Test Systems
    $AEHR
    3/25/2024Outperform → Mkt Perform
    William Blair
    Aehr Test Systems
    $AEHR
    10/17/2022Outperform
    William Blair
    More analyst ratings

    $AEHR
    $ATXI
    $BBLG
    $NINE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sims Andrew John Hugh Macintyre bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 42% to 68,138 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    11/5/25 8:30:03 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Director Lenk Robert P bought $53,779 worth of shares (110,000 units at $0.49), increasing direct ownership by 375% to 139,327 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    8/25/25 7:30:05 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Amendment: Large owner Monroe William bought $1,159,545 worth of shares (960,000 units at $1.21), increasing direct ownership by 25% to 4,863,000 units (SEC Form 4)

    4/A - Nine Energy Service, Inc. (0001532286) (Issuer)

    2/11/25 4:46:51 PM ET
    $NINE
    Oilfield Services/Equipment
    Energy

    $AEHR
    $ATXI
    $BBLG
    $NINE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

    HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. "Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness," said Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics. "Our recently completed upsized $15 million offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027." Overview of anticipated

    1/22/26 7:45:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

    HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call Date/Time:Thursday, January 22, 2026 @ 9:00 AM ETWebcast:https://event.choruscall.com/mediaframe/webcast.html?webcastid=x5QZCyIkParticipant Dial-in:1-888-349-0106   Please di

    1/21/26 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

    HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces the pricing of its underwritten public offering of 39,473,684 units, with each unit consisting of one share of common stock and one warrant (the "Warrants"). Each unit is being sold to the public at a price of $0.38 per unit. The gross proceeds to the Company from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each Warrant will be im

    1/14/26 8:00:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $AEHR
    $ATXI
    $BBLG
    $NINE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Aehr Test Systems with a new price target

    Lake Street initiated coverage of Aehr Test Systems with a rating of Buy and set a new price target of $29.00

    12/17/25 8:24:33 AM ET
    $AEHR
    Electrical Products
    Industrials

    Plus Therapeutics upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Plus Therapeutics from Hold to Buy and set a new price target of $5.00

    9/3/25 8:18:22 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $AEHR
    $ATXI
    $BBLG
    $NINE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP Contactor Business Unit Sporck Alistair N sold $82,716 worth of shares (3,000 units at $27.57), decreasing direct ownership by 11% to 25,153 units (SEC Form 4)

    4 - AEHR TEST SYSTEMS (0001040470) (Issuer)

    2/10/26 4:17:52 PM ET
    $AEHR
    Electrical Products
    Industrials

    Director Slayen Howard T gifted 15,000 shares, decreasing direct ownership by 7% to 203,328 units (SEC Form 4)

    4 - AEHR TEST SYSTEMS (0001040470) (Issuer)

    2/4/26 8:34:46 PM ET
    $AEHR
    Electrical Products
    Industrials

    EVP, PPBI BUSINESS Salamone Alberto covered exercise/tax liability with 234 shares, decreasing direct ownership by 0.30% to 76,906 units (SEC Form 4)

    4 - AEHR TEST SYSTEMS (0001040470) (Issuer)

    2/2/26 8:28:14 PM ET
    $AEHR
    Electrical Products
    Industrials

    $AEHR
    $ATXI
    $BBLG
    $NINE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Nine Energy Service Inc.

    SCHEDULE 13G/A - Nine Energy Service, Inc. (0001532286) (Subject)

    2/6/26 5:54:44 PM ET
    $NINE
    Oilfield Services/Equipment
    Energy

    Nine Energy Service Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Nine Energy Service, Inc. (0001532286) (Filer)

    2/6/26 6:03:39 AM ET
    $NINE
    Oilfield Services/Equipment
    Energy

    SEC Form 25-NSE filed by Nine Energy Service Inc.

    25-NSE - Nine Energy Service, Inc. (0001532286) (Subject)

    2/5/26 10:37:03 AM ET
    $NINE
    Oilfield Services/Equipment
    Energy

    $AEHR
    $ATXI
    $BBLG
    $NINE
    Leadership Updates

    Live Leadership Updates

    View All

    Mission Critical Group Appoints Julie Peffer as Chief Financial Officer

    MCKINNEY, Texas, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Mission Critical Group ("MCG"), a critical power infrastructure company specializing in the design, manufacturing, delivery, and service of advanced electrical systems, today announces the appointment of Julie Peffer as Chief Financial Officer. Peffer brings more than three decades of experience leading financial operations and strategic growth initiatives across global organizations, including Amazon Web Services (AWS), Flowserve, Raytheon, Lennox International, and Textron. She joins MCG from BigBear.ai (NYSE:BBAI), where she served as CFO and guided the company's financial strategy through rapid expansion in the defense and artificial

    10/21/25 8:05:00 AM ET
    $BBAI
    $NINE
    Computer Software: Prepackaged Software
    Technology
    Oilfield Services/Equipment
    Energy

    Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

    Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC's, Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT). Recent accomplishments include expansion of the CNSide manufacturing footprint,

    10/21/25 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

    HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee. "Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus' board of directors," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Furthermore, in his

    4/23/25 8:00:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $AEHR
    $ATXI
    $BBLG
    $NINE
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

    HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. "Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness," said Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics. "Our recently completed upsized $15 million offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027." Overview of anticipated

    1/22/26 7:45:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

    HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call Date/Time:Thursday, January 22, 2026 @ 9:00 AM ETWebcast:https://event.choruscall.com/mediaframe/webcast.html?webcastid=x5QZCyIkParticipant Dial-in:1-888-349-0106   Please di

    1/21/26 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

    US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the third quarter ended September 30, 2025 and provides an overview of recent and upcoming business highlights. "Our team continues to execute solidly across the three most important business verticals: diagnost

    10/30/25 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $AEHR
    $ATXI
    $BBLG
    $NINE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Avenue Therapeutics Inc.

    SC 13G - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/14/24 3:22:45 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care